Advenio
Advenio is an India-based healthcare AI company that builds Adven-i, a browser-based teleophthalmology platform using proprietary AI to detect retinal abnormalities from Fundus Camera images for healthcare providers and eye care institutions.
- Company typePrivate
- Founded2016
- HeadquartersChandigarh, India
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Advenio does
Advenio (legal entity Advenio Tecnosys Pvt. Ltd., previously known as ChironX) is an India-based healthcare AI company that builds AI-driven predictive diagnostic tools, anchored by its browser-based teleophthalmology platform Adven-i. Adven-i analyzes images from third-party Fundus Cameras using the company's proprietary AI algorithms, applying explainable AI, causal machine learning, computer vision, and advanced image processing to detect retinal abnormalities with self-reported accuracy above 94%. The platform runs in Chrome on standard laptops, desktops, and tablets without dedicated hardware installation, and the company offers a clinical validation page alongside the product.
The company sells to eye hospitals, ophthalmology clinics, diabetic care providers, and broader healthcare institutions through a usage-based SaaS model. Customers prepay for usage via Advenio's cPanel payment platform (cPanel.advenio.app or cPanel.advenio.dev), with refunds linked to actual usage. Distribution combines direct enterprise sales with demo-driven conversion (a free demo can be booked on the company website) and self-serve onboarding through its telemed.advenio.app platform. The Advenio Telemed System extends the offering into broader remote consultation and health record management.
Commercially, Advenio operates primarily within India and has built credibility through grants from BIRAC (SBIRI), Government of India, and the Bill and Melinda Gates Foundation, USA, alongside participation in accelerator and impact programs including Zone Startups India's empoWer, Unreasonable Group / Barclays, and Start Tel Aviv. The company is led by Mausumi Acharyya (PhD, ISI and University of Pennsylvania, ex-Siemens and GE) and a small leadership team including a Business Head, Sr. VP Product, and product marketing manager, with 11-50 employees and offices in Kolkata (headquarters) and Karnal.
Advenio firmographics
Firmographics- Name
- Advenio
- Legal name
- Advenio Tecnosys Pvt. Ltd.
- Website
- https://adveniotecnosys.tech
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Advenio is an India-based healthcare AI company that builds Adven-i, a browser-based teleophthalmology platform using proprietary AI to detect retinal abnormalities from Fundus Camera images for healthcare providers and eye care institutions.
- Ownership category
- akta.pro rank
Advenio industry classification
Industry- Product category
- AI Teleophthalmology Software
- akta.pro primary industry
- Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)
Keywords
Where Advenio is headquartered
LocationHeadquarters
- HQ city
- Chandigarh
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
Advenio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- SaaS Subscription - Advenio Telemed System: Advenio operates on a SaaS (Software as a Service) model where customers are charged based on usage. Users must do prepaid recharge through Advenio's cPanel payment platform (cPanel.advenio.app or cPanel.advenio.dev). The system supports online payments through third-party payment gateways.
- Usage-Based Recharge: Customers prepay for services through the cPanel platform and are charged per usage. Cancellation policy provides partial refunds: 100% refund before usage, remaining balance refunded after usage.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Usage-based SaaS with prepaid recharge model |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Advenio product offering
Product offeringCore offering
Advenio develops and sells an AI-driven teleophthalmology platform (Adven-i) that analyzes retinal images from third-party Fundus Cameras through a browser-based interface, using proprietary AI algorithms to detect retinal abnormalities with above 94% accuracy. It also offers the Advenio Telemed System, a SaaS telemedicine platform for remote consultations and health record management, sold on a prepaid, usage-based subscription to healthcare providers.
Product overview
Advenio offers an AI-driven healthcare diagnostic ecosystem consisting of two main products: the Adven-i platform, an AI-based teleophthalmology solution that works in browsers to detect retinal abnormalities using proprietary algorithms (achieving above 94% accuracy), and the Advenio Telemed System, a SaaS-based telemedicine platform for remote consultations and health record management. Both products integrate Fundus Camera hardware for data input and utilize the company's predictive diagnostic AI capabilities to serve healthcare providers and patients.
Differentiator
Problem solved
Functional benefit
Brands
- Adven-i: AI-based teleophthalmology platform for detecting retinal abnormalities with accuracy above 94%, operating through web browsers.
- Advenio TecnoSys
Products and services
- Adven-i AI-based teleophthalmology platform that runs in a web browser (Chrome on laptops, desktops, tablets) and analyzes images from third-party Fundus Cameras using Advenio's proprietary AI algorithms to detect retinal abnormalities with above 94% accuracy, targeted at eye hospitals, ophthalmology clinics, and diabetic care providers.
- Advenio Telemed System SaaS-based telemedicine platform that enables remote medical consultations and health record management for healthcare providers and their patients.
Quantifiable outcome
- Retinal abnormality detection accuracy above 94%
Companies that use Advenio
Customer profileSegments2 records
Ideal customer profiles2 records
Advenio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Advenio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Unreasonable Group (USA)coreFounder Mausumi Acharyya is a Fellow of Unreasonable, USA. Advenio participated in Unreasonable Impact Asia Pacific 2018 in Hong Kong organized by Unreasonable Group and Barclays Bank. The founder also pitched at Royal Institute of Great Britain, UK at Impact World Forum Event 2018.
- Barclays BankcorePartnered with Barclays Bank through the Unreasonable Impact Asia Pacific programme, supporting companies creating jobs for the future. Featured in Livemint article highlighting Barclays and Unreasonable's support for impact ventures.
- Zone Startups IndiacoreAdvenio was selected for Zone Startups India's empoWer accelerator programme, supporting women entrepreneurs. The programme was covered in Times of India and YourStory, providing media exposure and startup ecosystem access.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Advenio competitors and assessment
Company assessmentDirect peers
- Digital Diagnostics (IDx-DR): US-based pioneer of FDA-cleared autonomous AI for diabetic retinopathy detection (IDx-DR). Most direct comparable to Adven-i in product category, clinical use case, and B2B healthcare provider channel.
- Eyenuk: Developer of the EyeArt AI system, one of the most widely deployed FDA-cleared AI platforms for autonomous diabetic retinopathy screening. Directly competes with Adven-i in retinal disease AI screening for healthcare providers.
- Remidio Innovative Solutions: India-based ophthalmic device and AI-screening company that combines portable fundus cameras with AI-based DR screening. Closest India-headquartered peer to Advenio with overlapping teleophthalmology use cases.
- Forus Health: Bengaluru-based ophthalmic-device company (3nethra series) that has expanded into AI-driven retinal screening for DR and other conditions. Competes head-to-head with Advenio in Indian eye-care screening deployments.
Emerging players
- Aravind Eye Hospital (Eye-PACS / AI initiatives): Large Indian hospital network developing in-house and partnered AI tools for teleophthalmology and population-scale DR screening. Comparable as both a potential customer and a deployer of competing AI screening workflows in India.
- VoxelCloud: AI medical imaging company with retinal/diabetic-retinopathy screening among its diagnostics portfolio. Comparable as a peer-stage AI-healthcare startup targeting similar disease-screening workflows.
Broad incumbents
- Google Health (Verily / retinal AI): Has published and piloted AI models for retinal disease screening (including DR) and is a broad incumbent with vastly larger R&D and distribution resources. Represents the dominant strategic threat in the AI-ophthalmology category.
- Topcon Healthcare: Global ophthalmic equipment vendor expanding into AI-driven screening and disease detection via its Harmony/Imagenet platforms. Comparable as a vertically integrated fundus-camera-plus-AI incumbent in the same screening workflow.
- ZEISS Medical Technology: Major ophthalmic device and diagnostics company offering fundus imaging plus integrated AI screening workflows. Competes with Advenio at the procurement layer for eye hospitals and screening programs.
- Optos (Nikon Healthcare): Specialist in ultra-widefield retinal imaging whose devices and AI image-management software are commonly used in DR and AMD screening pipelines. Adjacent incumbent to Advenio in the fundus-imaging-and-screening ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Advenio social profiles
Digital presenceAdvenio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Advenio leadership team
Management profileNumber of profiles
Profiles4 records
Advenio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Advenio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Advenio
What does Advenio do?
Advenio develops and sells an AI-driven teleophthalmology platform (Adven-i) that analyzes retinal images from third-party Fundus Cameras through a browser-based interface, using proprietary AI algorithms to detect retinal abnormalities with above 94% accuracy. It also offers the Advenio Telemed System, a SaaS telemedicine platform for remote consultations and health record management, sold on a prepaid, usage-based subscription to healthcare providers.
Is Advenio a public or private company?
Advenio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Advenio founded?
Advenio was founded in 2016. It employs 11 to 50 people.
Where is Advenio based?
Advenio is headquartered in Chandigarh, India, in the Asia region.
How does Advenio make money?
Two revenue lines are on record. SaaS Subscription - Advenio Telemed System is the primary driver. The others are usage-Based Recharge.
Who are Advenio's main competitors?
Direct peers on record are Digital Diagnostics (IDx-DR), Eyenuk, Remidio Innovative Solutions and Forus Health. Emerging players are Aravind Eye Hospital (Eye-PACS / AI initiatives) and VoxelCloud. Broad incumbents are Google Health (Verily / retinal AI), Topcon Healthcare, ZEISS Medical Technology and Optos (Nikon Healthcare).
Does Advenio have an API?
No public API is recorded for Advenio.
What industry is Advenio in?
Advenio's product category is AI Teleophthalmology Software. Its primary akta.pro industry code is HLALAGAL, Ophthalmology & Vision Telemedicine Platforms.